Facilitate multidisciplinary collaborative research in non-Cystic Fibrosis (CF) bronchiectasis.

Bronchiectasis has historically been a neglected "orphan" disease. The international EMBARC network is focused on building capacity to perform high impact clinical trials and observational studies in bronchiectasis

Bringing in the expertise in AI-based image analysis, Thirona quantifies the extent and severity of bronchiectasis. Adding objectively quantified data to the EMBARC Registry will contribute to the longitudinal observational study of the open, pan-European registry of patients with non-CF bronchiectasis.

Bronchiectasis has historically been an under-researched and under-resourced disease. As it is now recognized as a disease that places an increasing burden on healthcare systems around the world, there is an urgent need for better treatments and for clinical and translational research for this condition. Developing new treatments requires multinational cooperation and coordination, so the EMBARC project forms an important platform for improving the disease knowledge and approach to treatment

EMBARC is the first international bronchiectasis network seeking to bring together investigators from around the world. Central to the project is the patient registry with non-CF bronchiectasis. This study will enable a group of experienced researchers across Europe to answer fundamental question sin the epidemiology, aetiology, microbiology, pathophysiology, clinical management and prognosis of bronchiectasis. Multiple publications demonstrate the value of EMBARC from its inception in 2012.